Unforced Error: Reata’s Decision To Ignore US FDA Endpoint Advice May Haunt Bardoxolone

 
• By Sarah Karlin-Smith
women with fingers in her ears
Reata’s decision to ignore FDA trial design advice likely to backfire. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers